New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.19, Iss.7, 2010-07, pp. : 837-846

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

By Mitsogiannis Iraklis C Skolarikos Andreas Deliveliotis Charalambos

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 493-501

Informa Healthcare

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis Leon Carlos Wasan Kishor

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite

Editorial (Thematic Issue: Novel Theraputic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 2-5

Bentham Science Publishers

Access to resources Recommend Favorite